Press Releases

Date Title and Summary Additional Formats
Toggle Summary ArQule Announces Exercise of over-Allotment Option
ArQule Announces Exercise of over-Allotment Option WOBURN, Mass.--(BUSINESS WIRE)--July 18, 2007--ArQule, Inc. ("ArQule" or the "Company") (NASDAQ: ARQL) today announced the closing of the purchase of an additional 502,000 shares of the Company's common stock pursuant to the underwriters' partial
View HTML
Toggle Summary ArQule Announces Completion of Common Stock Offering
ArQule Announces Completion of Common Stock Offering WOBURN, Mass.--(BUSINESS WIRE)--June 19, 2007--ArQule, Inc. (NASDAQ: ARQL) today announced the completion of its offering of 7,000,000 shares of common stock at $7.75 per share, representing an aggregate public offering price of approximately
View HTML
Toggle Summary ArQule Announces Offering of Common Stock
ArQule Announces Offering of Common Stock WOBURN, Mass.--(BUSINESS WIRE)--June 14, 2007--ArQule, Inc. ("ArQule" or the "Company") (NASDAQ: ARQL) announced today the pricing of an underwritten public offering of 7,000,000 shares of its common stock at a public offering price of $7.75 per share.
View HTML
Toggle Summary ArQule Announces Offering of Common Stock
ArQule Announces Offering of Common Stock WOBURN, Mass.--(BUSINESS WIRE)--June 6, 2007--ArQule, Inc. ("ArQule" or the "Company") (NASDAQ: ARQL) announced today that it has filed a preliminary prospectus supplement to an existing shelf registration statement with the Securities and Exchange
View HTML
Toggle Summary Data from ArQule's Phase 1 Trial with c-Met Inhibitor, ARQ 197, Demonstrate Safety and Expanded Anti-Cancer Activity
Objective responses and prolonged stable disease observed across broad range of doses and tumors
View HTML
Toggle Summary ArQule Files Shelf Registration Statement
ArQule Files Shelf Registration Statement WOBURN, Mass., May 23, 2007 (BUSINESS WIRE) -- ArQule, Inc. (NASDAQ: ARQL) today announced that it has filed a universal shelf registration statement with the Securities and Exchange Commission (SEC) that, upon being declared effective by the SEC, will
View HTML
Toggle Summary ArQule Reports First Quarter 2007 Financial Results
ArQule Reports First Quarter 2007 Financial Results WOBURN, Mass.--(BUSINESS WIRE)--May 3, 2007--ArQule, Inc. (NASDAQ: ARQL) today announced its financial results for the first quarter of 2007. For the quarter ended March 31, 2007, the Company reported a net loss of $14,504,000 or $0.40 per share,
View HTML
Toggle Summary ArQule and Kyowa Hakko Kogyo Sign Exclusive License Agreement in Asia for ARQ 197, c-Met Inhibitor
ArQule and Kyowa Hakko Kogyo Sign Exclusive License Agreement in Asia for ARQ 197, c-Met Inhibitor WOBURN, Mass.--(BUSINESS WIRE)--April 27, 2007--ArQule, Inc. (NASDAQ: ARQL) today announced that it has entered into an exclusive license agreement with Kyowa Hakko Kogyo Co., Ltd.
View HTML
Toggle Summary ArQule, Inc. to Report First Quarter 2007 Financial Results on May 3, 2007
Conference call and Webcast scheduled for 9:00 a.m. Eastern Time
View HTML
Toggle Summary ArQule to Present at Fortis Biotechnology Conference on April 25, 2007
Live webcast scheduled for 9:15 a.m. eastern time (14:15 p.m. UK)
View HTML

Questions or Concerns?

Please feel free to contact by one of the methods below

Online Form   Call (781) 994-0300

These archived presentations and related materials are provided for reference by ArQule, Inc. Information contained in the materials was current only as of the date of the event. ArQule, Inc. does not update or delete outdated information contained in these materials, and it expressly disclaims any obligation to do so. The materials are property of ArQule, Inc. and any use, dissemination or republication of the files is prohibited without the express written consent of ArQule, Inc.